1,3,4-Oxadiazoles as Anticancer Agents: A Review

Among the deadliest diseases, cancer is characterized by tumors or an increased number of a specific type of cell because of uncontrolled divisions during mitosis. Researchers in the current era are concentrated on the development of highly selective anticancer medications due to the substantial toxicities of conventional cytotoxic drugs. Several marketed drug molecules have provided resistance against cancer through interaction with certain targets/growth factors/enzymes, such as Telomerase, Histone deacetylase (HDAC), Methionine aminopeptidase (MetAP II), Thymidylate synthase (TS), Glycogen synthase kinase-3 (GSK), Epidermal growth factor (EGF), Vascular endothelial growth factor (VEGF), Focal adhesion kinase (FAK), STAT3, Thymidine phosphorylase, and Alkaline phosphatase. The molecular structure of these drug molecules contains various heterocyclic moieties that act as pharmacophores. Recently, 1,3,4-oxadiazole (fivemembered heterocyclic moiety) and its derivatives have attracted researchers as these have been reported with a wide range of pharmacological activities, including anti-cancer activities. 1,3,4- oxadiazoles have exhibited anti-cancer potential via acting on any of the above targets. The presented study highlights the synthesis of anti-cancer 1,3,4-oxadiazoles, their mechanism of interactions with targets, along with structure-activity relationship concerning anti-cancer potential.